Phosphatidylinositol 4-phosphate 3-kinase catalytic subunit type 2 alpha (PIK3C2A) mRNA (PIK3C2A mRNA)

Phosphatidylinositol 4-phosphate 3-kinase catalytic subunit type 2 alpha (PIK3C2A) is a Class II phosphoinositide 3-kinase (PI3K) that plays a distinct role from the more commonly targeted Class I PI3Ks. It is primarily involved in regulating vesicular trafficking, endocytosis, and the structural integrity of primary cilia by catalyzing the synthesis of PI3P and PI(3,4)P2 (UniProt O00443, PubMed: 31112133). PIK3C2A is essential for various physiological processes, including insulin-stimulated glucose uptake and angiogenesis (NCBI Gene: 5286, PubMed: 33408215). In oncology, PIK3C2A is frequently overexpressed and contributes to tumor progression, making its mRNA a potential target for gene-silencing therapies (PubMed: 34155112). However, its critical role in ciliary function means that systemic inhibition could lead to ciliopathy-like side effects, such as skeletal and neurological abnormalities (PubMed: 33408215). The target also encompasses other mRNAs within the PI3K/AKT signaling axis, such as AKT1 and PIK3CA, which are frequently targeted by antisense technologies to treat cancer and metabolic diseases (PubMed: 25135992). While small molecule inhibitors typically target the PI3K protein, the use of antisense oligonucleotides (ASOs) or siRNAs targeting the mRNA of PIK3C2A and other pathway components offers a method to selectively reduce the expression of these signaling nodes.

Other names

PI3K-C2-alpha mRNAPI3K-C2A mRNACPK mRNAPhosphoinositide 3-kinase class II alpha mRNAPI3K/AKT pathway mRNAsPIK3C2A and other PI3K/AKT pathway component mRNAs

RNA interference or antisense-mediated degradation of target mRNA transcripts to prevent protein translation.